Stenotrophomonas maltophilia: Emergence of multidrug-resistant strains during therapy and in an in vitro pharmacodynamic chamber model

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 12, 1996, Pages 2859-2864

  Garrison, Mark W ^a   Anderson, Donald E ^b   Campbell, Douglas M ^b   Carroll, Karen C ^c   Malone, Connie L ^a,b   Anderson, Jeffrey D ^a,b   Hollis, Richard J ^d   Pfaller, Michael A ^d  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Deaconess and Sacred Heart Medical Centers   (United States)

^c ARUP LABORATORIES   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; TIMENTIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; MULTIDRUG RESISTANCE; MUTATION RATE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA;

EID: 0029826627     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.12.2859     Document Type: Article

References (30)

1. Anderson, D. E., M. W. Garrison, D. M. Campbell, K. C. Carroll, C. L. Malone, J. D. Anderson, R. J. Hollis, and M. A. Pfaller. 1994. Emergence of ceftazidime resistant Stenotrophomonas maltophilia during ceftazidime therapy and in an in vitro pharmacodynamic chamber model, abstr. D-62, p. 125. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. BioMerieux Vitek, Inc. 1993. Product information, API 20E system for identification of Enterobacteriaceae and other gram negative bacteria. BioMerieux Vitek, Inc., Hazelwood, Mo.
3. Campbell, D. M., S. Cohen, K. C. Carroll, J. D. Claridge, M. W. Garrison, J. M. Kramp, C. L. Malone, and D. E. Anderson. 1994. Comparison of four in vitro susceptibility methods for testing Stenotrophomonas maltophilia, abstr. D-60, p. 125. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Chapin-Robertson, K., and S. C. Edberg. 1991. Measurement of antibiotics in human body fluids: techniques and significance, p. 313. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams and Wilkins, Baltimore.
5. Cullmann, W. 1991. Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates. Chemotherapy 37:246-250.
6. Elting, L. S., N. Khardori, G. P. Bodey, and V. Fainstein. 1990. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect. Control Hosp. Epidemiol. 11:134-138.
7. Felegie, T. P., V. L. Yu, L. W. Rumans, and R. B. Yee. 1979. Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination. Antimicrob. Agents Chemother. 16:833-837.
8. Garrison, M. W., K. Vance-Bryan, T. A. Larson, J. P. Toscano, and J. C. Rotschafer. 1990. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 34:1925-1931.
9. Herman, V. K., F. N. Konstantinides, R. A. Zabinski, J. C. Rotschafer, and F. B. Cerra. 1991. Abstract 336. In Program and abstracts of the Annual Meeting of the Federation of American Societies for Experimental Microbiology.
10. Hohl, P., R. Frei, and P. Aubry. 1991. In vitro susceptibility of 33 clinical case isolates of Xanthomonas maltophilia. Inconsistent correlation of agar dilution and of disk diffusion test results. Diagn. Microbiol. Infect. Dis. 14:447-450.
11. Khardori, N., L. Elting, E. Wong, B. Schwable, and G. P. Bodey. 1990. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev. Infect. Dis. 12:997-1003.
12. Laing, F. P., K. Ramotar, R. R. Read, N. Alfieri, A. Kureishi, E. A. Henderson, and T. J. Louie. 1995. Molecular epidemiology of Xanthomonas maltophilia colonization and infection in the hospital environment. J. Clin. Microbiol. 33:513-518.
13. Lesco-Bornet, M., J. Pierre, D. Sarkis-Karam, S. Lubers, and E. Bergogne-Berezin. 1992. Susceptibility of Xanthomonas maltophilia to six quinolones and the study of outer membrane proteins in resistant mutants selected in vitro. Antimicrob. Agents Chemother. 36:669-671.
14. Malone, C. L., D. E. Anderson, M. W. Garrison, and M. Hoffman. 1995. In vivo vs in vitro efficacy of sulfamethoxizole-trimethoprim for Stenotrophomonas maltophilia, the need to validate synergy studies, abstr. D-20, p. 70. In Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Washington, D.C.
15. Manian, F. A., and R. H. Alford. 1986. Discrepancies between disk diffusion and broth susceptibility studies of the activity of ticarcillin plus clavulanic acid against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 30: 35-38.
16. Marshall, W. F., M. R. Keating, J. P. Anhalt, and J. M. Steckelberg. 1989. Xanthomonas maltophilia: an emerging nosocomial pathogen. Mayo Clin. Proc. 64:1097-1104.
17. Mett, H., S. Rosta, B. Schacher, and R. Frei. 1988. Outer membrane permeability and beta-lactamase content in Pseudomonas maltophilia clinical isolates and laboratory mutants. Rev. Infect. Dis. 10:765-769.
18. Morrison, A. J., K. K. Hoffman, and R. P. Wenzel. 1986. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J. Clin. Microbiol. 24:52-55.
19. National Committee for Clinical Laboratory Standards. 1993. Zone diameter interpretive standards and equivalent MIC breakpoint for organisms other than Haemophilus, Neisseria and Streptococcus pneumoniae, 5th ed. Approved standard. Pocument M2-A5. National Committee for Clinical Standards, Villanova, Pa.
20. National Committee for Clinical Laboratory Standards. 1994. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard, document M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
21. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1994. Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxicin, PD131628, PD138312, PD140248, ciprofloxacin, and ofloxacin. Antimicrob. Agents Chemother. 38:369-370.
22. Pankuch, G. A., M. R. Jacobs, S. F. Rittenhouse, and P. C. Appelbaum. 1994. Susceptibilities of 123 strains of Xanthomonas maltophilia to eight β-lactams (including β-lactam-β-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrob. Agents Chemother. 38:2317-2322.
23. Pfaller, M. A., R. J. Hollis, and H. S. Sader. 1994. Chromosomal restriction fragment analysis by pulsed field gel electrophoresis, p. 10.5C.1-10.5.C.12. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook, suppl. 1. American Society for Microbiology, Washington, D.C.
24. Poufos, C. D., S. O. Matsumura, B. M. Willey, D. E. Low, and A. McGeer. 1995. In vitro activities of antimicrobial combinations against Stenotrophomonas (Xanthomonas) maltophilia. Antimicrob. Agents Chemother. 39: 2220-2223.
25. Rolston, K. V. I., M. Messer, and D. H. Ho. 1990. Comparative in vitro activities of newer quinolones against Pseudomonas species and Xanthomonas maltophilia isolated from patients with cancer. Antimicrob. Agents Chemother. 34:1812-1813.
26. Sanders, C. C., J. P. Iaconis, G. P. Bodey, and G. Samonis. 1988. Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 β-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob. Agents Chemother. 32:1365-1369.
27. Sanders, C. C., and W. E. Sanders, Jr. 1986. Type 1 beta-lactamases of the gram-negative bacteria: interactions with beta-lactam antibiotics. J. Infect. Dis. 154:792-800.
28. Vartivarian, S., E. Anaissie, G. Bodey, H. Sprigg, and K. Rolston. 1994. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob. Agents Chemother. 38: 624-627.
29. Vartivarian, S. E., K. A. Konstantinos, J. A. Palacios, J. T. Manning, Jr., and E. J. Anaissie. 1994. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. Ann. Intern. Med. 121:969-973.
30. Villarino, M. E., L. E. Stevens, B. Schwable, G. Mayers, J. M. Miller, J. P. Burke, and W. R. Jarvis. 1992. Risk factors for epidemic Xanthomonas maltophilia infections/colonizations in the intensive care unit patient. Infect. Control Hosp. Epidemiol. 13:201-206.